Purpose of review Acute and chronic kidney diseases (AKI and CKD) have far-reaching implications for surgical patients in regards to postoperative outcomes and hospital cost. We review the recent literature on the effects of AKI and CKD on morbidity, mortality, and resource utilization among cardiac surgery patients.
INTRODUCTION
Acute kidney injury (AKI) and chronic kidney diseases (CKD) are associated with increased short-term and long-term morbidities and mortality across multiple patient populations [1] [2] [3] [4] [5] [6] . Both preoperative CKD and postoperative AKI have been linked to worse operative outcomes, increased mortality, and more resource utilization [7, 8] . Cardiac surgery patients are particularly prone to the development of postoperative AKI given the disease burden at the time of surgery, the nature of the procedures, and the common use of cardiopulmonary bypass (CPB) [9] [10] [11] . Patients with preoperative CKD often have higher incidences of cardiovascular comorbidities that may require operative intervention, such as coronary artery disease, silent myocardial ischemia, valvular disease, and arrhythmias [4, 12] . Despite ongoing efforts to develop diagnostic and interventional strategies to identify, mitigate, and even prevent postoperative renal dysfunction, both CKD and AKI remain prevalent and costly conditions among cardiac surgical patients.
OUTCOMES: MORTALITY
AKI has repeatedly been shown to increase shortterm and long-term mortalities across multiple patient populations, both surgical and nonsurgical [2,5,7,13,14 & ,15,16,17 && ]. Postoperative AKI is associated with increased in-hospital mortality, with increasing severity of AKI stage correlating with worse outcomes [1] [2] [3] 17 && ,18]. Machado et al. [19] demonstrated that among postoperative coronary artery bypass grafting (CABG) patients with elevated preoperative serum creatinine, 76% of those who developed stage 3 AKI required renal replacement therapy (RRT), of which 66% died within 30 days. Even patients with the mildest forms of cardiac surgery-associated acute kidney injury (CSA-AKI), RIFLE-R class, have higher rates of in-hospital mortality and length of stay [8] . Higher long-term mortality persists for postoperative AKI patients when followed as long as up to 10 years, with survival differences as much as 44 versus 63% for AKI and no AKI, respectively at 10 years [1, 2, 20] . This long-term mortality differential persists even for those patients with postoperative AKI who have complete recovery of renal function by the time of discharge from the hospital [1, 16, 17 && ]. A significant prognostic indicator appears to be the duration of CSA-AKI. Brown et al. [21] showed that longer durations of AKI were associated with both increased in-hospital mortality (15.3% for AKI lasting 7 days or longer compared to 4.1% for AKI lasting 1-2 days) and reduced 5-year survival (hazard ratio 3.40 for AKI lasting 7 days or longer compared to hazard ratio 1.66 for AKI lasting 1-2 days). Similarly, Swaminathan et al. [22] demonstrated that early renal recovery after AKI had better long-term survival, with the most significant predictor of 1-year survival being the percentage decrease of serum creatinine within 24 h of its peak.
Patients with CKD are known to have higher rates of cardiovascular comorbidities such as coronary artery disease, arrhythmias, silent ischemia, and valve disease [4, 12] . It has recently been shown that patients with postoperative AKI have high rates of cardiovascular specific mortality after major surgery, similar to that known to occur in patients with CKD [14 & ]. CKD has been shown to be an independent predictor of in-hospital mortality and morbidity, and worse clinical outcomes are associated with more severe stages of CKD [6, [23] [24] [25] . In a cohort of 7621 patients undergoing CABG, valve, or combined procedures, the odds ratios of in-hospital mortality were 1.45, 2.8, and 7.5 for CKD stages 2, 3, and 4, respectively. In this same cohort, the hazard ratios for late mortality were 1.2, 1.95, and 3.2 for CKD stages 2, 3, and 4, respectively when followed out to a median of 42 months [23] . Hedley et al. [24] demonstrated an increase in operative mortality of 35-43% for every decrease of 10 ml/min/1.73 m 2 in preoperative estimated glomerular filtration rate (eGFR) in patients undergoing CABG. Even minimal increases in preoperative serum creatinine or decreases in eGFR that still remain within established normal reference ranges have been associated with increased mortality, infection, RRT requirement, and cerebrovascular accidents [26] .
As previously described, patients with preoperative renal dysfunction are at an increased risk of developing postoperative AKI [19, 27] , even those patients who exhibit proteinuria without an observed decrease in eGFR [28, 29 && ]. Given the increased mortality and morbidity associated with CKD and AKI independently, the effects of these complications are worse when they occur together [6, 7, 14 & ].
OUTCOMES: MORBIDITY
Postoperative AKI is associated with significant morbidity in addition to mortality. Patients with AKI also had higher rates of other postoperative complications, including infection, mechanical ventilation duration, and cerebrovascular and cardiovascular events [7, 15, 16, 30] . Hansen et al.
[30] calculated the 5-year risk of a composite cardiovascular endpoint of myocardial infarction, heart failure, or stroke to be 24.9% for patients with postoperative AKI after cardiac surgery compared with 12.1% for patients with no AKI. Among a large single-center cohort, 79% of patients who developed AKI also developed at least one other postoperative complication after major surgery [7] . The risk of developing CKD after episodes of AKI has been shown to be increased in patients with previously normal renal function and increases with worsening severity of AKI class [17 && ,31,32]. Coca et al. [31] demonstrated pooled hazard ratios of 8.8 and 3.1 for CKD and end-stage renal disease (ESRD) respectively among all surgical patients with postoperative AKI. In a large retrospective cohort of major surgical patients, only 56% of those who developed postoperative AKI achieved full renal recovery by the time of hospital discharge [16] . Not surprisingly, patients with the most severe cases of AKI are at the highest risk for long-term renal dysfunction, with 80% of those requiring acute RRT developing CKD stage 3 or worse at 30 months in a single cohort study of both medical and surgical
KEY POINTS
AKI and CKD contribute to increased postoperative morbidity and mortality that increases proportionally with increasing severity of disease.
The mortality risk in patients with AKI is present even in those who recover full renal function.
Patients with preoperative CKD are at increased risk of developing postoperative AKI, and patients with AKI are at increased risk of developing CKD.
AKI and CKD contribute to longer lengths of stay and higher hospital costs that increase with worsening disease severity.
COST
In addition to mortality and morbidity, postoperative AKI contributes significantly to increased hospital lengths of stay, cost, and resource utilization. An early study, published before the adoption of consensus definitions of AKI, estimated that one episode of hospital-based AKI resulted in nearly $7500 in excess costs and that hospital-based AKI resulted in annual expenditures, which exceed $10 billion [35] . In a large cohort of patients undergoing major surgery, patients who developed postoperative AKI incurred a total hospital cost of 159% higher than those patients who did not suffer renal dysfunction, with a mean adjusted cost of $42 600 compared to $26 700. In this study median costs were highest for patients with AKI who died, followed by patients with AKI who survived, and lowest for patients with no AKI (Fig. 1a) . These patients had mean ICU and total hospital lengths of stay of 6 days and 12 days, respectively, compared with 2 days and 5 days for those patients who did not develop AKI. The costs increased proportionally with increasing severity of AKI, with additional attributable costs of $10 700, $21 400, and $38 200 for RIFLE classes R, I, and F, respectively [7] . In this study the adjusted cumulative incremental cost of individual postoperative complications was also examined, for patients with and without postoperative AKI. Although all complications were associated with higher costs, a concurrent episode of AKI dramatically increased the cumulative incremental cost, especially for patients with pulmonary and cardiovascular complications (Fig. 1b) . Similar results were shown by Dasta et al. [8] in post-CABG patients, wherein total postoperative cost averaged $37 674 for patients with CSA-AKI compared to $18 463 for those without, as well as increased ICU and total hospital lengths of stay, all of which increased proportionally with worsening AKI class. The increased costs were observed across various subcategories of care including the ICU, medical supply, laboratory, pharmacy, and respiratory services.
For patients undergoing transcatheter aortic valve replacement (TAVR) in Great Britain, AKI was among the postoperative complications with the highest attributable cost. For stage 3 AKI, the additional s20 468 incurred was second only to life threatening bleeding from a nonaccess site, and was more expensive than requiring the placement of a second valve [36 & ]. Similar results were observed in a recent study of TAVR patients in the USA, with hospital lengths of stay twice as long and costs 50% higher for patients who sustained postoperative AKI [37] .
Patients with CKD also sustain higher costs and resource utilization in the perioperative setting. In a cohort of major vascular surgery patients, the presence of either CKD or postoperative AKI contributed to a 23% higher total hospital costs, with adjusted incremental costs of $8900 and $9100, respectively. When both of these conditions were present, hospital costs were 49% higher with adjusted incremental cost of $19 100 [38
The cost of AKI and CKD for surgical patients is not limited to that attributable to the hospital stay. These patients also incur higher costs after hospital discharge. In a study of cardiothoracic surgery patients, 90% of patients without postoperative AKI were discharged to their home from the hospital compared to only 68% of patients who developed AKI during their hospitalization [1] . Those who did not return home were discharged either to a longterm acute care facility, skilled nursing facility, or some other form of short-term rehabilitation center. These discharge dispositions burden patients with financial hardships that are not captured in hospital cost reports, along with the intangible costs associated with not returning home directly. Although reduced lengths of stay may improve hospital costs, the costs and resource utilization that the patient experiences may not be significantly improved overall but simply shifted more towards the postdischarge setting [39] .
DISCUSSION
CKD and AKI are common postoperative conditions, whose pervasiveness is now apparent with the adoption of consensus definitions of AKI, and whose impacts are being described in the studies that now use these consensus definitions. Postoperative complications have been shown to be more important overall than preoperative risks and intraoperative factors in determining short-term and long-term survivals after surgery [40] . Cardiac surgery patients in particular are more likely to have pre-existing CKD and are at higher risk for the development of postoperative AKI than other surgery patients. Preoperative screening of patients undergoing cardiac surgery, to identify those patients who are at risk for postoperative AKI including especially those patients with pre-existing CKD, is essential if the impact of these conditions is to be minimized. Appropriate perioperative and postoperative management of the cardiac surgery patient is also important. The large increases in cost and mortality that result from the concurrent occurrence of AKI with other postoperative complications emphasize the importance of identifying and treating preoperative CKD and preventing postoperative AKI if possible.
CONCLUSION
Acute and chronic kidney diseases remain prevalent and morbid conditions for cardiac surgical patients. When they occur ICU lengths of stay, hospital lengths of stay, resource utilization, and both in-hospital and post-discharge costs dramatically increase. Identification of preoperative CKD, better risk stratification for the patient about to undergo cardiac surgery, better preventive strategies for perioperative AKI, earlier identification and intervention for the patient who sustains postoperative AKI, and ultimately better therapies for those patients with either CKD or AKI are needed.
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